Dr. William J. Calhoun, MD
Pulmonology (Pulmonary Disease Physician)
301 University Blvd
Galveston, TX 77555
Who else practices at this address →
Galveston County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 147
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TX license N1274 (first issued 2008; active) -
Allergy & Immunology (Internal Medicine) Physician
TX license N1274 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 147
- Services billed
- 323
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test to determine lung volumes using sensors | 85 | 85 |
| Test to examine how well the lungs exchange gases | 84 | 84 |
| Test to measure expiratory airflow and volume | 70 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 40 |
| Test for exercise-induced lung stress | 41 | 40 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Galveston, TX | 43 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Galveston, TX | 30 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Galveston, TX | 28 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in Galveston, TX | 26 |
| Fluticasone Propionate Other prescribers in Galveston, TX | 20 |
| Dupixent Pen (dupilumab) Other prescribers in Galveston, TX | 18 |
| Spiriva Handihaler (tiotropium bromide) Other prescribers in Galveston, TX | 16 |
| Prednisone Other prescribers in Galveston, TX | 15 |
| Breyna (budesonide/formoterol fumarate) Other prescribers in Galveston, TX | 11 |
| Prolastin C (alpha-1-proteinase inhibitor) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 17 payments worth $51,746 in total to this clinician.
| Genzyme Corporation | $31,218 |
|---|---|
| Aquestive Therapeutics, Inc. | $13,426 |
| Regeneron Healthcare Solutions, Inc. | $7,102 |
| Compensation for services other than consulting (speaking, faculty) | $33,931 |
|---|---|
| Travel and Lodging | $8,775 |
| Consulting Fee | $8,625 |
| Food and Beverage | $414 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $9,863 |
| Aquestive Therapeutics, Inc. Aug 5, 2025 | Consulting Fee LIBERVANT · Central Nervous System | $8,625 |
| Regeneron Healthcare Solutions, Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,129 |
| Aquestive Therapeutics, Inc. Aug 5, 2025 | Travel and Lodging LIBERVANT · Central Nervous System · travel to NEWARK, NJ | $4,801 |
| Genzyme Corporation Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,340 |
| Genzyme Corporation Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,551 |
| Genzyme Corporation May 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,551 |
| Genzyme Corporation May 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to South Portland, ME · in-kind | $2,999 |
| Genzyme Corporation Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,762 |
| Genzyme Corporation Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,762 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,762 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,973 |
| Aquestive Therapeutics, Inc. Aug 5, 2025 | Consulting Fee LIBERVANT · Central Nervous System | $8,625 |
| Aquestive Therapeutics, Inc. Aug 5, 2025 | Travel and Lodging LIBERVANT · Central Nervous System · travel to NEWARK, NJ | $4,801 |
| Regeneron Healthcare Solutions, Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,129 |
| Genzyme Corporation May 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,551 |
| Genzyme Corporation May 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $9,863 |
| Genzyme Corporation May 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to South Portland, ME · in-kind | $2,999 |
| Genzyme Corporation May 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to South Portland, ME · in-kind | $601 |
| Genzyme Corporation May 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to South Portland, ME · in-kind | $374 |
| Genzyme Corporation Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,340 |
| Genzyme Corporation Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,551 |
| Genzyme Corporation Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,762 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $11,276 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK)
AstraZeneca Pharmaceuticals LP - Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
Sanofi US Services Inc. · Completed · NCT05326412
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.